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ABSTRACT
Background Bilirubin has anti-oxidative and anti-inflammatory properties, which may explain its proposed
protective effects on the development of cardiometabolic disorders. Glucocorticoids affect heme oxygenase
regulation in vitro, which plays a key role in bilirubin production. Effects of variations in glucocorticoid exposure
on circulating bilirubin levels in humans are unknown. Here we tested whether a higher hydrocortisone
replacement dose affects circulating bilirubin in hypopituitary patients.
Materials and methods A randomized double-blind cross-over study (ClinicalTrials.gov, number
NCT01546992) was performed in 47 patients with secondary adrenal failure [10-week exposure to a higher
hydrocortisone dose (04–06 mg/kg body weight) vs. 10 weeks of a lower hydrocortisone dose (02–03 mg/kg
body weight)].
Results Plasma total bilirubin was increased by 10% from 7 to 8 lM in response to the higher hydrocortisone
dose (P = 0033). This effect was inversely related to age (P = 0042), but was unaffected by sex, obesity and
(replacement for) other hormonal insufficiencies. The higher hydrocortisone dose also resulted in lower alkaline
phosphatase (P = 0006) and aspartate aminotransferase activities (P = 0001).
Conclusion Bilirubin is modestly increased in response to higher glucocorticoid exposure in humans, in con-
junction with lower alkaline phosphatase and aspartate aminotransferase activities, which are supposed to
represent biomarkers of a pro-inflammatory state and enhanced liver fat accumulation.
Keywords Alkaline phosphatase, bilirubin, hydrocortisone, secondary adrenal insufficiency, transaminases.
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Introduction
Bilirubin is able to scavenge peroxyl radicals, to diminish low-
density lipoprotein (LDL) oxidation, to decrease the expression
of cellular adhesion molecules and to inhibit the production of
pro-inflammatory cytokines [1–3]. Furthermore, circulating
bilirubin levels are inversely related to the inflammation
markers, high-sensitivity C-reactive protein and serum amyloid
A, as well as to a composite measure of circulating glycosylated
acute-phase proteins [4–6]. Among other mechanisms, anti-
oxidative and anti-inflammatory properties are believed to
explain the proposed protective effects of bilirubin on the
development of cardiometabolic disorders [3]. In line, bilirubin
is inversely associated with intima media thickness, a marker of
subclinical atherosclerosis [7,8], as well as with incident car-
diovascular disease [9,10].
The heme oxygenase (HO) system is crucial for the genera-
tion of bilirubin from heme [3,11,12]. Expression of the HO-1
isoenzyme is inducible by a variety of factors, whereas the HO-
2 isoenzyme is considered to be expressed in a predominantly
constitutive fashion [11,12]. Interestingly, the HO-2 gene con-
tains a functional glucocorticoid response element [11]. As a
result, HO-2 transcripts and protein levels are upregulated by
glucocorticoids in vitro at least in neonatal rat brain and testis
[13–15]. On the other hand, upregulation of HO-1 by inter-
leukin-6 may be counteracted by glucocorticoids in endothelial
cells [16].
Given the alleged influence of bilirubin on cardiometabolic
disorders [3], it is pathophysiologically relevant to determine
the contribution of glucocorticoids to bilirubin regulation, but
no data are available with respect to effects of variation in
glucocorticoid exposure on circulating bilirubin levels in
humans. We have recently conducted a randomized cross-over
study in hypopituitary patients with secondary adrenal insuf-
ficiency (ClinicalTrials.gov, number NCT01546992) which is
aimed at assessing effects of a higher compared to a lower
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hydrocortisone replacement dose on cognitive function, quality
of life and metabolic parameters [17]. The present ancillary
analyses were performed to test whether the degree of hydro-
cortisone exposure affects circulating bilirubin levels in this
patient category.
Patients and methods
Participants and study design
Reporting of the study conforms to CONSORT and the broader
EQUATOR guidelines [18]. This randomized double-blind
cross-over study was performed in a university hospital setting
in Groningen, the Netherlands. The study has been registered
with ClinicalTrials.gov, number NCT01546992, and has been
approved by the medical ethics committee of the University
Medical Center Groningen, the Netherlands. All participants
provided written informed consent. The rationale and design of
the study have been provided in detail elsewhere [17]. Fig-
ure S1 shows eligibility, inclusion and follow-up of the partic-
ipants. In brief, hypopituitary patients with established
secondary adrenal insufficiency (based on internationally
accepted criteria) were eligible for this randomized
double-blind cross-over study. They were recruited from the
outpatient endocrinology clinic of the University Medical
Center, Groningen, the Netherlands. The following inclusion
criteria were applied: treatment for pituitary disorder (surgery
and/or radiotherapy) at least 1 year before study entry, stable
replacement therapy for other pituitary hormone deficiencies
for at least 6 months (thyroid hormone deficiency, growth
hormone deficiency, testosterone/estradiol deficiency, diabetes
insipidus), age between 18 and 75 years and body weight
between 50 and 100 kg [17]. Main exclusion criteria were major
cognitive impairment, drug abuse, current psychiatric disor-
ders, shift work, malignancy, previous Cushing’s disease, a
history of frequent episodes of hypocortisolism, medically
treated diabetes possibly leading to hypoglycaemia (insulin,
sulfonylurea) and anti-epileptic drugs [17]. Subjects experienc-
ing a hospital admission during the study were also excluded.
Before entry in the study, all patients who were treated with
cortisone acetate were switched to hydrocortisone in a bioe-
quivalent dose during a 4-week run-in period [17]. The
hydrocortisone dose administered during the run-in period
averaged 25 mg (031 mg/kg body weight) per day. The par-
ticipants were then randomized to a lower hydrocortisone dose
during 10 weeks followed by a higher hydrocortisone dose
during another 10-week period or vice versa. The lower
hydrocortisone dose was 020–030 mg hydrocortisone per kg
body weight per day divided into three doses, taken before
breakfast, before lunch and before dinner. A double dose, also
divided into three doses and taken at the same time points, was
administered during the higher hydrocortisone dose period.
Hydrocortisone administration was performed in a double-
blind fashion using 5-mg tablets in the lower and 10-mg tablets
in the higher hydrocortisone replacement period. In case of
intercurrent illnesses, doubling or tripling the hydrocortisone
dose was allowed for 7 days maximally (+10% of the cumula-
tive study dose). Compliance to hydrocortisone tablet intake
was verified as described [17]. Sixty-three patients were initially
randomized of whom 47 completed the study. Reasons for
withdrawal were described elsewhere [17]. All these 47 subjects
were included in the present analysis. Twenty-two patients
received the lower hydrocortisone dose first, whereas 25
participants were first given the higher hydrocortisone dose.
Detailed clinical characteristics of the participants, including
medical history, cause of secondary adrenal insufficiency and
other hormone replacement therapies, have been provided
elsewhere [17].
Venous blood was obtained after an overnight fast at 8 a.m.;
that is, 1 h after the morning hydrocortisone dose was taken.
Twenty-four-hour urine collections were obtained 1 day before
the scheduled visits at the end of the lower and higher hydro-
cortisone periods. Body mass index was calculated as body
weight (in kg) divided by length (in m) squared.
Laboratory analyses
Plasma and serum samples were prepared by centrifugation at
4 °C. The samples were then stored at 80 °C until analysis.
Total bilirubin was measured in heparinized plasma by a
colorimetric assay (Roche, Mannheim, Germany). The detection
limit was 17 lM. The intra-assay coefficient of variation (CV)
was < 2% at the lower normal range. In healthy subjects,
bilirubin is most abundantly present in plasma in its unconju-
gated form [19]. In a validation experiment (n = 80), a strong
correlation between total bilirubin and unconjugated bilirubin
(Spearman’s r = 092, P < 0001), as well as between total
bilirubin and conjugated direct bilirubin (Spearman’s r = 082,
P < 0001) was observed. For this study, we only used total
bilirubin in agreement with other reports [5,6,8–10].
Plasma alkaline phosphatase (ALP), alanine transferase
(ALT), aspartate aminotransferase (AST) and gamma-gluta-
myltransferase (GGT) were routinely measured on a Roche
Modular platform. All tests were performed according to the
International Federation of Clinical Chemistry recommenda-
tions. ALT and AST were measured with pyridoxal phosphate
activation. The intra-assay coefficients of variation (CVs) were
< 25%.
Serum cortisol was measured by electrochemiluminescence
immunoassay (Roche Modular Systems, Mannheim, Germany;
intra-assay CV < 2%). Urinary free cortisol was analysed by
automated online solid phase extraction in combination with
liquid chromatography tandem–mass spectrometry (XLC-MS/MS)
(intra-assay CV < 25%).
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Statistical analysis
Sample size calculation and information regarding the ran-
dom allocation sequence and its implementation have been
provided elsewhere [17]. Data are presented as mean  SD or
as median (interquartile range). Because of skewed distribu-
tion total bilirubin, ALP, ALT, AST, GGT and urinary free
cortisol excretion were natural log-transformed to achieve
approximately normal distributions. Changes are presented as
mean (95% confidence intervals) for parametrically dis-
tributed variables and as median (interquartile range) for
nonparametrically distributed variables. The effect of higher
vs. lower hydrocortisone dose on the various variables was
compared by Student’s t-tests. The univariate relationships of
changes in bilirubin with continuous and dichotomous base-
line variables were tested using Pearson’s correlation coeffi-
cients and unpaired Student’s t-tests, respectively. To check
for period and treatment by period interaction effects (carry-
over effect), the procedure developed by Altman was used
[20].
Results
Twenty-nine men and 18 women completed the study. At
entry, mean age at entry was 52  14 years, and mean body
mass index was 270  40 kg/m2. Thyroid hormone was
diagnosed in 92% of patients and replaced in all; growth hor-
mone deficiency was diagnosed in 66% and replaced in 68%;
testosterone deficiency was diagnosed 79% of men and
replaced in all; eight women were premenopausal in whom
estradiol deficiency was diagnosed in 50% and treated in all
(postmenopausal estradiol deficiency not replaced); and dia-
betes insipidus was diagnosed in 19% and replaced in all.
Baseline clinical characteristics were provided elsewhere [17].
The various hormonal substitution regimens were left
unchanged during the 4-week run-in period, as well as during
the 10-week lower and higher hydrocortisone replacement
periods. A doubling of the hydrocortisone dose as stress-
related dose adjustment was reported 159 times on the low
dose (16% of the total dose administrations) and 146 times on
the high dose (15% of the total dose administrations).
Doubling of the hydrocortisone dose elicited an increase in
serum cortisol, as well as in urinary free cortisol excretion
(Table 1). Body mass index was slightly increased with the
higher hydrocortisone dose, but plasma glucose was
unchanged (Table 1). On average, total bilirubin was increased
by 10% during the higher dose of hydrocortisone, whereas
serum ALP and AST activity were slightly decreased (Table 1;
Fig. 1). ALT and GGT activity did not significantly change. In
univariate analysis, the increase in total bilirubin was inversely
related to age (r = 0298, P = 0042), but was related neither to
sex, BMI, the use of thyroid hormone, the use of sex steroids,
growth hormone deficiency, diabetes insipidus and plasma
glucose (P > 029 for all), nor to the sequence of the lower and
higher hydrocortisone doses (P = 035). No period or treatment
by period interaction effects was found for all the outcome
measures (all P > 005).
Table 1 Body mass index, estimates of cortisol metabolism, plasma glucose, plasma total bilirubin, alkaline phosphatase activity,
transaminase activities and c-glutamyltransferase (GGT) activity during randomized periods of lower and higher hydrocortisone
replacement doses in 47 hypopituitary patients with secondary adrenal insufficiency.
Lower dose Higher dose Change P-value
Hydrocortisone dose (mg/day) 1793  223 3585  446 1793 (1729–1856) < 0001
Body mass index (kg/m2) 270  40 272  41 02 (00–03) 0026
Serum cortisol (1 h after intake; nM) 643  241 918  245 275 (206–345) < 0001
Urinary free cortisol (nmol/24 h) 78 (46–111) 274 (199–408) 207 (131–314) < 0001
Fasting plasma glucose (mM) 524  09 521  08 003 (018–012) 070
Plasma total bilirubin (lM) 7 (5–12) 8 (6–11) 1 (1–2) 0033
Plasma ALP activity (U/L) 60 (48–73) 55 (47–73) 2 (9–2) 0006
Plasma AST activity (U/L) 26 (22–31) 22 (20–28) 3 (7–0) 0001
Plasma ALT activity (U/L) 21 (16–33) 19 (15–29) 1 (7–3) 0085
Plasma GGT activity (U/L) 23 (16–33) 23 (18–34) 1 (2–4) 030
Data in mean  SD or median (interquartile range). Changes are given in mean with 95% confidence intervals (CI) for parametrically distributed data or as
median (interquartile range) for nonparametrically distributed data. ALP, alkaline phosphatase activity; ALT, alanine transferase activity; AST, aspartate
aminotransferase activity; GGT, c-glutamyltransferase activity.
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Discussion
This randomized double-blind cross-over study demonstrates
to our knowledge for the first time that a higher hydrocortisone
replacement regimen increases circulating bilirubin levels in
hypopituitary subjects with secondary adrenal insufficiency.
This effect appeared to be less outspoken in older individuals,
but was unrelated to sex, obesity, fasting glucose and (re-
placement for) other hormonal deficiencies. Moreover, we
could rule out confounding due to carry-over effects of the
higher and the lower hydrocortisone replacement doses. The
present findings are, therefore, consistent with the notion that
variations in glucocorticoid exposure affect bilirubin metabo-
lism in humans.
In view of the supposition that bilirubin levels reflect overall
status of HO activity [21], our results consent with the
hypothesis that glucocorticoids stimulate HO expression in
humans. While this possibility agrees with previous results in
rodent models [13–15], it is obvious that the current findings do
not allow to discern between differential effects of hydrocorti-
sone on specific HO isoforms nor in specific tissues. Further-
more, it should be noted that bilirubin levels are also
determined by biliary elimination via uridine diphosphate
glucuronosyltransferase 1A1, which conjugates bilirubin and
enables bilirubin elimination [3]. This enzyme is induced by
glucocorticoids in HepG2 cells [22,23]. Although an opposing
contribution to the glucocorticoid increasing effects on circu-
lating bilirubin via uridine diphosphate glucuronosyltrans-
ferase 1A1 stimulation cannot be excluded, short-time
glucocorticoid administration does not affect biliary bilirubin
output in humans [24].
Doubling the hydrocortisone replacement dose expectedly
increased serum cortisol and urinary free cortisol excretion, and
may have resulted in mild hypercortisolism in some individu-
als [25]. The increase in serum bilirubin in response to the
higher hydrocortisone replacement regimen averaged 10%.
While this previously unreported bilirubin response may have
pathophysiological relevance, its clinical significance is uncer-
tain. Based on large prospective cohort studies and meta-ana-
lysis, the risk of incident cardiovascular disease has been
estimated to be about 18% lower per doubling of the bilirubin
level [9,10]. In this context, the impact of the observed bilirubin
increase on cardiovascular risk is likely to be small. Of note, we
also documented a drop in ALP activity in response to a higher
hydrocortisone replacement dose. As ALP is regarded as an
inflammatory biomarker [26,27], this finding may point to less
chronic low-grade inflammation consequent to modestly higher
glucocorticoid exposure [28]. However, a limitation of our
study is that we did not measure other inflammation markers
such as high-sensitivity C-reactive protein.
It is pertinent that overt hypercortisolism coincides with
hepatic fat accumulation [29,30]. However, plasma AST activity
was also modestly decreased after the higher hydrocortisone
replacement dose. Considering that this enzyme may provide a
biomarker of liver fat accumulation [31,32], this finding would
be consistent with some beneficial effect on nonalcoholic fatty
liver disease (NAFLD) development, putatively consequent to
higher bilirubin levels [33]. In addition, it seems possible that
the increasing effect of a higher hydrocortisone dose on plasma
bilirubin could provide a potentially relevant additional
mechanism which contributes to the anti-inflammatory role
commonly ascribed to glucocorticoids [28].
Several other methodological issues and limitations of our
study need to be discussed. First, our trial was performed in
hypopituitary patients with established secondary adrenal
insufficiency to rule out confounding due to coexisting miner-
alocorticoid deficiency – in particular on cognitive parameters –
as much as possible. Consequently, extrapolation to other
patient categories is limited. Second, our study was not
designed to establish glucocorticoid dose- and time-dependent
effects on circulating bilirubin. However, the present compar-
ison of a lower and higher hydrocortisone replacement regimen
puts the changes in bilirubin in a physiological perspective as
much as possible. Additionally, it seems plausible that 10-week
administration periods are sufficient to establish a steady state
of altered glucocorticoid exposure to various metabolic pro-
cesses. We believe the same holds true for a 4-week run-in
period in particular given the fact that the total daily hydro-
cortisone dose during the run-in period was lower than that
during the higher hydrocortisone dose replacement period.
Third, all participants received adequate replacement treatment
for other pituitary hormone deficiencies if deemed clinically
Figure 1 Plasma total bilirubin in response to higher vs. lower
hydrocortisone replacement doses. Natural log-transformed
(Ln) values of plasma bilirubin are shown. Bars indicate
mean  SE values. *P = 0033.
478 ª 2016 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd
on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
J. WERUMEUS BUNING ET AL. www.ejci-online.com
necessary. Replacement doses with thyroid hormone, growth
hormone, sex steroids and desmopressin were left unchanged
during the study. This approach was chosen to limit coexisting
effects of other hormonal factors on bilirubin metabolism
[34,35].
In conclusion, circulating bilirubin is modestly increased in
response to higher glucocorticoid exposure. Our findings sup-
port the hypothesis that glucocorticoids contribute to bilirubin
metabolism in humans.
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